211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary and a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
282 articles with Daiichi Sankyo
Specific financial terms of the agreement have not been disclosed.
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event
Findings Will Be Presented at Academy of Managed Care Pharmacy (AMCP) Nexus Industry Workshop
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma
Treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal (thymus) large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL) and transformed follicular lymphoma (TFL), which are aggressive forms of non-Hodgkin lymphoma (NHL).
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML).
Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Over 97 percent of eligible claimants have opted into the product liability litigation settlement program announced on August 1, 2017 for cases brought against various Daiichi Sankyo and Forest entities.
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
5/15/2018Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.
New campaign aims to educate people about Iron Deficiency Anemia, a condition that affects 36 to 76 percent of people with inflammatory bowel diseases.
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
- Global phase 2 study will evaluate efficacy and safety of DS-8201 in patients with HER2-expressing advanced colorectal cancer who have received at least two prior lines of standard treatment
2/23/2018The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.
Daiichi Sankyo Initiates Phase I Study of U3-1402 in Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Treatment with EGFR TKIs such as erlotinib, gefitinib, or afatinib is used as first-line therapy for metastatic EGFR-mutated NSCLC.
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients With HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Updated preliminary subgroup analysis results in 44 of 45 efficacy evaluable patients with HER2-expressing gastric cancer or gastroesophageal junction adenocarcinoma previously treated with trastuzumab and chemotherapy showed that DS-8201 demonstrated a confirmed overall response rate of 45.5 percent and a disease control rate of 81.8 percent.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
Daiichi Sankyo's Once-Daily, Oral SAVAYSA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
The Hokusai-VTE CANCER study met the primary objective of non-inferiority of edoxaban for the composite outcome of first recurrent VTE or ISTH-defined major bleeding during a 12-month study period.
Daiichi Sankyo Presents Phase I Data for EZH1/2 Dual Inhibitor DS-3201 in Patients With Non-Hodgkin Lymphomas at the 59th Annual Meeting of the ASH
Preliminary exploratory efficacy results from an ongoing phase 1 dose escalation study showed that an overall response rate of 58.8 percent was observed with single agent DS-3201 in 17 evaluable patients with NHLs, including B-cell and T-cell lymphomas, who were relapsed from or refractory to standard treatment or for whom no standard treatment was available.